Results 41 to 50 of about 32,499 (205)

Clinical and Immunological Outcomes after Initiation of Second Line Antiretroviral Therapy in People Living with HIV [PDF]

Journal of Clinical and Diagnostic Research, 2019
Introduction: Resistance to first-line Antiretroviral Therapy (ART) has been a major concern in People Living with HIV (PLHIV), which necessitates a switch to second-line therapy.
BASAVAPRABHU ACHAPPA, DEEPAK MADI, MOHAMMAD YOUSUFF, SATISH RAO, JOHN RAMAPURAM   +4 more
doaj   +1 more source

Aspartic Protease Inhibition Induces Proteomic Remodeling in Paracoccidioides brasiliensis

PROTEOMICS, EarlyView.
ABSTRACT Paracoccidioidomycosis (PCM) is a major systemic mycosis in Latin America caused by Paracoccidioides brasiliensis, yet the contribution of aspartic proteases to fungal physiology and pathogenicity remains poorly understood. Here, we employed data‐independent acquisition (DIA)‐based quantitative proteomics to investigate the impact of pepstatin
Sarah Fernandes Lima, Wilson Dias Segura, Leonardo Brogliato de Moraes, Reinaldo Souza Oliveira, Pedro Henrique Corteletti Manfio, Alison Felipe Alencar Chaves, Wagner Luiz Batista   +6 more
wiley   +1 more source

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV

, 2008
Background: Prior attempts to reduce the number of drugs needed to maintain viral suppression in patients with suppressed HIV replication while receiving three antiretroviral drugs have been unsuccessful.
Pulido Ortega, Federico, Rubio García, Rafael, Norton, Michael   +2 more
core   +1 more source

Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment

Pharmaceuticals, 2022
The combination of lopinavir/ritonavir remains one of the first-line therapies for the initial antiretroviral regimen in pediatric HIV-infected children.
Azizah M. Malebari, Aytug Kara, Ahdab N. Khayyat, Khadijah A. Mohammad, Dolores R. Serrano   +4 more
doaj   +1 more source

HIV viral suppression in children and adolescents who transitioned from ritonavir‐boosted lopinavir‐ to dolutegravir‐based antiretroviral therapy in Lesotho

HIV Medicine, EarlyView.
Abstract Objectives Children and adolescents living with HIV previously taking ritonavir‐boosted lopinavir (LPV/r)‐based antiretroviral therapy (ART) have been programmatically transitioned to dolutegravir (DTG)‐based regimens in many country programs.
Jacob Blankenberger, Teresa L. F. Steffy, Tristan Lee, Thithili Makhesi, Meenakshi Bakaya, Akash Devendra, Pheello Mothepu, Lipontso Motaboli, Nadine Tschumi, Anna Klicpera, Tapiwa Tarumbiswa, Frédérique Chammartin, Lineo K. Thahane, Niklaus D. Labhardt, Jennifer A. Brown   +14 more
wiley   +1 more source

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis

, 2009
Background: The OK04 trial has shown that 48 weeks of lopinavir-ritonavir monotherapy with reintroduction of nucleosides as needed was noninferior to continuation of triple therapy with 2 nucleosides and lopinavir-ritonavir in patients with prior stable ...
Pulido Ortega, Federico, Rubio García, Rafael, Arribas, Jose R.   +2 more
core   +1 more source

Lopinavir pharmacokinetics in COVID-19 patients

, 2020
International audienceThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in late 2019. Therapeutic solutions are currently being tested for COVID-19, the SARS-CoV-2-associated pneumonia.
Gaborit, Benjamin, Grégoire, Matthieu, Lecomte, Raphaël, Le Turnier, Paul, Canet, Emmanuel, Veyrac, Gwenaelle, Boutoille, David, Bellouard, Ronan, Raffi, François, Imbert, Berthe-Marie   +9 more
core   +1 more source

Structural and molecular characterization of lopinavir and ivermectin as breast cancer resistance protein (BCRP/ABCG2) inhibitors

EXCLI Journal : Experimental and Clinical Sciences, 2023
A current clinical challenge in cancer is multidrug resistance (MDR) mediated by ABC transporters. Breast cancer resistance protein (BCRP) or ABCG2 transporter is one of the most important ABC transporters implicated in MDR and the use of inhibitors is a
Julia de Paula Dutra, Gustavo Scheiffer, Thales Kronenberger, Lucas Julian Cruz Gomes, Isadora Zanzarini, Kelly Karoline dos Santos, Arun K. Tonduru, Antti Poso, Fabiane Gomes de Moraes Rego, Geraldo Picheth, Glaucio Valdameri, Vivian Rotuno Moure   +11 more
doaj   +1 more source

Maternal nutrition as a key determinant of placental and developing blood–brain barrier xenobiotic protective functions

The Journal of Physiology, EarlyView.
Abstract figure legend Suboptimal maternal nutrition alters placental and developing blood–brain barrier (BBB) protective function and is associated with increased fetal brain vulnerability. In the placenta, nutritional adversity may reduce the exchange surface area and promote meta‐inflammation, compromising barrier efficiency in a model‐ and context ...
Kristin L. Connor, Nycolle I. S. Souza, Bruno G. Anjos, Stephen G. Matthews, Enrrico Bloise   +4 more
wiley   +1 more source

Enhanced Eryptosis Following Exposure to Lopinavir [PDF]

, 2015
Background/Aims: The protease inhibitor lopinavir, used for the treatment of HIV infections, triggers suicidal death or apoptosis of nucleated cells.
Abdulla Al Mamun Bhuyan, Salem Abbès, Rosi Bissinger, Rosi Bissinger, Florian Lang, Ghada Bouguerra, Sabrina Waibel   +6 more
core   +1 more source